Punjab Chemicals Q1 FY26 Earnings Analysis

- New products launched in FY '24 and FY '25 contribute around 12% of revenue and are expected to grow at 15%-20% annually for the next 2-3 years. - Base business is expected to grow about 20% in FY '26, assuming current pricing levels are maintained. - Overall revenue growth guidance is in the range of 18%-20%. - Maintaining market share amid subdued demand, with volumes steady but impacted by pricing decreases in recent years. - Capacity expansion planned to drive scaling, with new integrated production facility expected operational by end of FY '27 to potentially double revenue contribution. - Continued focus on new product pipeline, with advanced sample approvals, supporting sustained growth over coming years. - Expected improvement in margins and volumes as market recovers and pricing normalizes.

- Company expects ~20% growth in base business for FY '26 and FY '27 driven by volume recovery and market share maintenance. - New products (currently 12% of revenue) are expected to grow at 15%-20% annually over next 2-3 years, supporting top-line expansion. - Gross margins improved by 160 bps in FY '25 and are expected to further improve due to new product mix and operational efficiencies. - EBITDA margin for Q4 FY '25 rose to 12.6% from 6.7% YoY; target margin of ~18% over next 2-3 years with better product mix and contributions. - PAT margins improved by 230 bps YoY in Q4 FY '25; management expects profitability to trend upward with margin restoration and cost controls. - New greenfield capacity and R&D expansion aim to double revenue potential and deliver IRRs above 20%, indicating potential for earnings acceleration post-FY '27. - Working capital and cost efficiencies are expected to support margin expansion and sustainable profit growth.

- Punjab Chemicals is planning a Greenfield capex of INR 250-300 crores to be spent over 2-3 years, targeting completion by FY '27 (Page 6, 7, 17). - Capex financing will be a mix of internal accruals and external borrowing; the company is monitoring borrowing costs to optimize funding (Page 17). - This investment is for new capacity expansion to cater to increased demand, support product pipeline, and replace debottlenecking efforts (Page 7). - The new facility will focus on products going off-patent, customer-approved products, and new CDMO contracts, reflecting a robust demand outlook (Page 11). - Asset turnover expected from new capacity is about 2x-2.2x, with IRR target above 20% (Page 10, 11). - Expansion will support growth in phosphorus derivatives, aiming to nearly double phosphorus business revenues to INR 280-300 crores in 2-2.5 years (Page 14). - R&D team size is expected to double to support this growth and innovation (Page 17, 18).

- The company plans a capex of INR 250-300 crores over the next 2-3 years. - This capex will be financed through a mix of internal accruals and external borrowing. - External financing is expected to be in the form of loans, but it is yet undecided whether these will be domestic or foreign currency loans. - Management is closely monitoring borrowing costs and aims to keep debt levels controlled. - Current debt-equity ratio is comfortable at around 0.4, with borrowings at about INR 153 crores. - No specific mention of equity fundraising was made; focus is on debt financing for expansion. - The company is cautious about maintaining a manageable debt level while pursuing growth through capex.

- The company has created inventory strategically to honor its existing order book positions, with about INR25 crores of inventory lying in transit as of March 31, 2025 (Page 6). - Discussions indicate firm demand for existing products and new products, with sample approvals in advanced stages, reflecting a healthy product pipeline (Page 3). - There is visibility on new products ramping up, supported by customer approvals and ongoing contract manufacturing discussions (Page 11). - New facility capex is driven by increasing demand and product pipeline, with commercial production targeted by end of FY '27 (Pages 6-7). - Management expects growth of around 20% in base business and 15-20% in new product contribution in FY '26-'27, implying a positive orderbook visibility (Page 5). - No explicit quantified orderbook figures were disclosed, but management references firm orders and advanced discussions on CDMO contracts (Pages 7, 11). Hence, the company has a healthy and growing orderbook supported by strategic inventory build-up and active customer engagements.